VX-745 |cas:209410-46-8 |DC Chemicals|Supplier|Price|Buy  

VX-745  |cas 209410-46-8 |DC Chemicals|Supplier|Price|Buy

DC Chemicals  Supply: VX-745  ,cas 209410-46-8, Cat No. DC4173, In stock

Contact: website:www.dcchemicals.com,

sales@dcchemicals.com,order@dcchemicals.com,info@dcchemicals.com,

Tel: +86-21-61454686;Fax:+86-21-61642730；

Product name: VX-745, Synonym:　VX 745,VX745, Cat No. DC4173, Cas: 209410-46-8, Chemical Name:5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one, Molecular Formula: C19H9Cl2F2N3OS, MW: 436.26

VX-745 Cas#209410-46-8.Purity:99%.Best Price and Quality in the Market!Supplied by DC Chemicals! VX-745 is a potent and selective inhibitor of p38α MAPK and p38β MAPK with IC50 of 10 nM and 220 nM, respectively.

VX-745 is an antiarthritic Drugs. Its activities and application include: Myelodysplastic Syndrome Therapy, Oncolytic Drugs, Rheumatoid Arthritis, Treatment of, treatment of musculoskeletal & connective tissue diseases, Antiinflammatory Drugs, p38 Protein Kinase.

 

VX-745 is a lead anti-inflammatory candidate, small-molecule inhibitor of mitogen-activated protein kinase (MAPK), is under development by Vertex Pharmaceuticals Inc in association with Kissei Pharmaceutical Co Ltd for the potential treatment of rheumatoid arthritis (RA) . VX-745 was introduced by Vertex as a potential antiinflammatory drug for the treatment of RA in a pilot phase II trial initiated in November 1999. In June 2000, phase II trials were still ongoing and in January 2001, Vertex initiated a randomized, double-blind, placebo-controlled phase II trial in adult patients with RA, with the objective of evaluating clinical response rates, self-reported patient health assessments and pharmacodynamic markers of drug activity. During the 33rd Annual Meeting of the American Chemical Society in May 2000, VX-745 was reported to be active against several isotypes of p38 MAPK, including p38alpha, p38beta and p38gamma . The targeting of p38 MAPK by VX-745 was associated with the suppression of the release of inflammatory mediators, including interleukin (IL)-1beta and tumor necrosis factor (TNF)alpha, known to be implicated in exacerbating the pathophysiology of RA. [source: Curr Opin Investig Drugs. 2001 Aug;2(8):1070-6.]

 For the detailed information about the solubility of VX-745  in water, the solubility of VX-745  in DMSO, the solubility of VX-745  in PBS buffer, the animal experiment of VX-745 ,the in vivo and in vitro test of VX-745 ,the cell experiment of VX-745 ,the IC50 and EC50 of VX-745 please contact DC Chemicals.